Amide compounds acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arthritis, pruritus, asthma, multiple sclerosis, arrhythmia, heart failure and epilepsy, among others.
Eurofarma Laboratórios SA and Universidade Federal do Rio de Janeiro have patented N-acylhydrazone compounds acting as sodium channel protein type 9 subunit α (SCN9A; Nav1.7) and/or SCN10A (Nav1.8) blockers which are described as being potentially useful for the treatment of pain.
Gruenenthal GmbH has described substituted pyrazole amides acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Vertex Pharmaceuticals Inc. has divulged N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, Charcot-Marie-Tooth disease, cough, urinary incontinence and multiple sclerosis.
Several recent patents from Vertex Pharmaceuticals Inc. have disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, Charcot-Marie-tooth disease, cough, urinary incontinence and multiple sclerosis.
Merck Sharp & Dohme Corp. has described 3-oxopiperazine carboxamide derivatives acting as sodium channel protein type 10 subunit alpha (Nav1.8) blockers reported to be useful for the treatment of cough, pruritus, acute and neuropathic pain.
